Quarterly ResultMay 6, 2026, 07:52 AM
Bioventus Q1 Revenue $132.1M, GAAP EPS $0.04; Raises FY26 Guidance
AI Summary
Bioventus Inc. reported strong first-quarter 2026 financial results, with revenue increasing 7% to $132.1 million. The company achieved GAAP earnings of $0.04 per diluted share, a significant improvement from a loss in the prior year, and non-GAAP earnings of $0.15 per diluted share. Driven by accelerated cash flow and debt repayment, Bioventus raised its full-year 2026 guidance for Adjusted EPS and Cash from Operations, while reaffirming its net sales outlook.
Key Highlights
- Q1 reported revenue increased 7% to $132.1 million.
- Q1 GAAP diluted EPS was $0.04, improving from a $0.04 loss in the prior year.
- Q1 Non-GAAP diluted EPS rose 88% to $0.15.
- Q1 cash from operations was $8.9 million, up $28.3 million year-over-year.
- Made a $22.0 million discretionary principal prepayment on its term loan.
- Raised full-year 2026 Adjusted EPS guidance to $0.75-$0.79.
- Raised full-year 2026 Cash from Operations guidance to $84M-$89M.
- Reaffirmed full-year 2026 net sales guidance of $600M-$610M.
Price Impact
More from BVS